MD Anderson Cancer Center
1515 Holcombe Boulevard
309 articles about MD Anderson Cancer Center
Clinical Catch-Up: May 25-29
6/1/2020In the lead-up to the ASCO Annual Meeting, companies were presenting some of their trial data, while other companies were presenting news related to COVID-19 studies. Here’s a look.
Genprex Enters Into Exclusive Worldwide Patent and Technology License Agreement for Combination of its TUSC2 Gene Therapy with Immunotherapies
Licensed technologies include use of Genprex’s TUSC2 gene therapy combined with immunotherapy drugs
Clinical Catch-Up: April 27-May 1
5/4/2020There’s plenty of news related to clinical trials related to COVID-19, but it does seem to be drowning out non-COVID-19-related clinical trials. Here’s a look.
MD Anderson Cancer Center Now Enrolling Patients in Rafael Pharmaceuticals’ Phase 2 Clinical Trial of CPI-613® (devimistat) for Relapsed or Refractory Burkitt’s Lymphoma/Leukemia
Patients will be assessed in advance of enrollment to ensure safety, due to COVID-19 pandemic
NuProbe Announced New Clinical Advisory Board Members from Yale and MD Anderson, Launched NGS Multi-gene Panels
NuProbe, a molecular diagnostic startup, announced the addition of two world-renowned oncologists to their clinical advisory board: Amir A. Jazaeri, M.D., from the University of Texas MD Anderson Cancer Center and Abhijit Patel, M.D., Ph.D., from Yale University School of Medicine.
Bellicum Completes Sale of Houston Facility
Purchase price of $15 million from sale of manufacturing, office and laboratory facility
InxMed Announces Dosing of First Patient in a Phase Ib Trial of IN10018 as Monotherapy and Combination Therapy in Patients with Uveal Melanoma and NRAS mutant Metastatic Melanoma in the United States
InxMed Co., Ltd. announced that the company has dosed first patient in its Phase Ib clinical trial of IN10018 as monotherapy and in combination with MEKi in the patients either with metastatic uveal melanoma or NRAS mutant metastatic melanoma at The University of Texas M. D. Anderson Cancer Center, United States.
Soliton signs Agreement with Global Manufacturer Sanmina
Expects Delivery and Sales of Initial RAP Devices for Tattoo Removal in Mid-2020
Osteosarcoma profiling reveals why immunotherapy remains ineffective
Study points to strategies for improving outcomes with immunotherapy in rare cancer type
Intratumoral heterogeneity may be responsible for chemotherapy resistance in patients with small cell lung cancer
Small cell lung cancer accounts for 14% of all lung cancers and is often rapidly resistant to chemotherapy, resulting in poor clinical outcomes.
Clinical Catch-Up: February 10-14
2/17/2020It was a very busy week for clinical trial news. Here’s a look.
Clinical Catch-Up: February 3-7, 2020
2/10/2020Although it was a relatively slow week for clinical trial updates, there were still a number of announcements. Here’s a look.
The immuno-oncology therapy, CAR-T, utilizes specific types of immune cells, T-cells, which are drawn from the cancer patient, supercharged, and infused back into the patient. Now, The University of Texas MD Anderson Cancer Center has developed a slightly different approach using a different type...
Cell>Point Expanding Theranostic Clinical Research to Include Platinum and 177Lu Targeted Therapy to Compliment Oncardia® Imaging Platform
Cell>Point announced, based on its sponsored chelator and therapeutic research conducted at the University of Texas M.D. Anderson Cancer Center on Platinum-Oncardia and 177Lu-Oncardia, and the positive results of its lung cancer imaging trials with 99mTc-Oncardia®, that it will be moving forward with these two intra-nuclear therapeutics expanding its focus in theranostic medicine.
B-cell enrichment predictive of immunotherapy response in melanoma, sarcoma and kidney cancer
Multiple studies point to important role for B cells in promoting anti-tumor immunity
Soliton To Announce Keloid and Hypertrophic Scar Clinical 12-Week Trial Data at Maui Derm Meeting
Maui Derm for Dermatologies 2020 Meeting is being held from January 25-29, 2020, in Maui Hawaii
CNS Pharmaceuticals Licenses Breakthrough Technology from MD Anderson, Doubling its Drug Pipeline
CNS Pharmaceuticals, Inc. announced it has entered into a licensing agreement with MD Anderson to investigate WP1244, an entirely new class of DNA-binding agents designed to cross the blood brain barrier for the potential the treatment of primary and metastatic brain cancers.
Study shows protein inhibitor as potential treatment approach for common mutations found in non-Hodgkin lymphomas
Findings may create immunotherapy options for lymphomas caused by CREBBP mutations
Soliton Appoints Mary Stoll as Senior Director of Clinical Development
Soliton, Inc.,, a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center, announced the appointment of Mary Stoll as Senior Director of Clinical Development.
Aptose Presents New Preclinical CG-806 Data at the 2019 ASH Annual Meeting
Aptose Biosciences Inc. announced the presentation of preclinical data for its first-in-class, FLT3/BTK inhibitor CG-806 at the 61st American Society of Hematology Annual Meeting and Exposition in Orlando, FL.